Dr Caggiano will continue to manage the preclinical and R&D departments, as well as oversee Acorda’s preclinical programs that aim to develop novel approaches to the treatment of multiple sclerosis, spinal cord injury and related neurological disorders.
Dr Caggiano joined Acorda in September 2001 as a lab scientist, and throughout his seven years at the company has held various positions of increasing responsibility in the preclinical department.
Prior to joining Acorda, Dr Caggiano co-founded Remote Diagnostic Imaging, a company that assembled an expert staff of radiologists to provide remote diagnostic services to understaffed hospitals.
Ron Cohen, CEO of Acorda, said: “Since joining Acorda, Tony has made significant contributions in advancing our preclinical technologies, bringing novel and exciting protein therapeutics closer to clinical stage trials. Acorda has several promising technologies in our preclinical pipeline, and Tony and his team have proven expertise in the full range of preclinical initiatives necessary to move these therapies forward.”